ArticlePharmacogenomics and personalized medicine2026
Comparative Analysis of SLCO1B1 Gene Polymorphisms in Dyslipidemic and Normolipidemic Patients with Type 2 Diabetes Mellitus Residing at High Altitude.
Article in Pharmacogenomics and personalized medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To examine the association between SLCO1B1 gene polymorphisms and blood lipid metabolism in Tibetan patients with type 2 diabetes mellitus (T2DM) in Yushu, Qinghai, China. Methods: A cross-sectional study enrolled 156 Tibetan T2DM patients (78 normolipidemic and 78 dyslipidemic) admitted to Yushu People's Hospital between September 2022 and December 2023. SLCO1B1 521T>C and 388A>G polymorphisms were genotyped using PCR-RFLP. Results: The 521TC genotype frequency was significantly higher in the dyslipidemia group (30.8% vs. 14.1%, p < 0.05), with elevated triglycerides, total cholesterol, and low-density lipoprotein cholesterol (p < 0.01). Multivariate regression confirmed positive associations. The 388AG and 388GG genotypes were associated with elevated triglycerides (p < 0.05). Conclusion: SLCO1B1 521T>C and 388A>G polymorphisms are significantly associated with dyslipidemia in this high-altitude Tibetan T2DM population, with 521T>C showing stronger predictive potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.